Downstream Processing Featured Articles

1. The Medicines Company And Bristol-Myers Squibb Begin Global Alliance For Recothrom® 2/8/2013

   The Medicines Company (NASDAQ: MDCO) announced today that the global license and two-year collaboration for Recothrom®, a recombinant thrombin approved by the U.S.

2. Is The Single-Use Standardization Debate Slowing Down Adoption? 3/16/2015

   Without single-use standardization, the customization required to build a single-use facility may prevent a full-scale adoption of single-use technology. So how do we move forward? Maybe, by taking a look back.

3. Flu Shot During Pregnancy Shows Unexpected Benefits In Large Study 5/22/2012

   Getting a flu shot during pregnancy provides unanticipated benefits to the baby, according to the authors of a large population-based study examining the issue.

4. Millipore Unveils Mobius FlexReady Solutions At INTERPHEX 2009 3/17/2009
   Billerica, Massachusetts-Millipore Corporation, a Life Science leader providing technologies, tools and services for bioscience research and biopharmaceutical manufacturing, announces the launch of its Mobius FlexReady Solutions.
5. Alzheimer's Disease In Mice Alleviated Promising Therapeutic Approach For Humans 11/25/2012

   Alzheimer’s disease is one of the most common causes of dementia. In Germany and Switzerland alone, around 1.5 million people are affected, and forecasts predict a doubling of the number of patients worldwide within the next 20 years.

6. Boehringer Ingelheim Implements Flexible Fully Disposable Up- And Downstream Manufacturing For Biopharmaceuticals 9/10/2012

   Boehringer Ingelheim has developed and now implemented a flexible set-up and operational approach for disposable technologies within its global biopharmaceutical development and manufacturing network.

7. MMRGlobal Targets Phase 3 Biotech Companies To Combine Assets With Life Sciences Group 11/19/2012

   MMRGlobal, Inc. (OTCBB: MMRF) today announced that through its wholly owned subsidiary, MMR Life Sciences Group, the Company plans on exploiting its pipeline of biotech assets by facilitating a partnership or other joint venture with a privately held biotech company that has completed its Phase 2 clinical trials and is in the process of beginning Phase 3.

8. Unraveling The Molecular Roots Of Down Syndrome 3/24/2013

   What is it about the extra chromosome inherited in Down syndrome—chromosome 21—that alters brain and body development? Researchers have new evidence that points to a protein called sorting nexin 27, or SNX27.

9. Acceleron Initiates Phase 2 Study Of ACE-536 To Treat Patients With Beta-Thalassemia 3/7/2013

   Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, recently announced the initiation of a phase 2 study of its novel, investigational protein therapeutic, ACE-536, to treat patients with beta-thalassemia, a genetic hematologic disorder causing chronic and life-threatening anemia and serious complications affecting the spleen, liver and heart.

10. Galapagos Receives EUR2.5 Million IWT Grant For IBD Research 1/30/2013

    Galapagos NV (Euronext: GLPG) announced today that it has been awarded a EUR2.5 million grant from the Flemish agency for Innovation by Science and Technology (IWT) for inflammatory bowel disease (IBD) research and development. The goal of this 2.5-year project is to identify new therapeutic compounds for future treatment of IBD patients.